- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06315556
An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
Drug Utilization Study for Eylea 40 mg/mL Using the PICLEO Paediatric Dosing Device in Preterm Infants With Retinopathy of Prematurity in the UK
This is an observational study in which only data from babies with retinopathy of prematurity (ROP) who are being treated with aflibercept (Eylea) in prefilled syringe (PFS) using a paediatric dosing device (PDD) are collected and studied.
ROP is a condition that affects the eyes of preterm babies. It occurs when the baby's retina, the part of the eye that senses light, does not develop normally. This may result in vision problems, including blindness, if left untreated. Preterm babies are born before 37 weeks of pregnancy. ROP is more likely to develop in babies who are born before 32 weeks of pregnancy or weigh less than 1.5 kilograms at birth.
Aflibercept is a drug that is injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth of blood vessels in the retina.
Aflibercept in PFS given using a PDD is approved for the treatment of babies with ROP. The prefilled syringe will be fitted with an injection needle to give aflibercept. And a PDD is a tool used to give the right amount of aflibercept to children in a safe manner.
Since there are other treatments which are commonly used for babies with ROP, the extent of use of aflibercept given using a PDD is unknown.
The main purpose of this study is to:
- find the number of preterm babies who are treated with aflibercept using a PDD in the UK
- inform whether this number is enough to perform a study to learn about the long-term safety of aflibercept given using a PDD in babies with ROP
An additional purpose of this study is to describe characteristics including age, sex, and race, and signs and symptoms of ROP observed in babies being treated with aflibercept using a PDD.
The data will come from a database called the National Neonatal Research Database. The study will cover the period from March 2024 to March 2025, if the number of babies found is enough to perform the safety study. If not, data will be collected till April 2027.
In this study only available data from preterm babies born during the study period are collected. No visits or tests are required as part of this study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Bayer Clinical Trials Contact
- Phone Number: (+)1-888-84 22937
- Email: clinical-trials-contact@bayer.com
Study Locations
-
-
-
Multiple Locations, United Kingdom
- Recruiting
- Many Locations
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Eligible infants within the NNRD include those who were:
- 1. Born during the study period, i.e. from Q4/2023 following market introduction of Eylea PFS+PDD and 31st December 2026, and
- 2. Received care in a neonatal unit that contributes data to the NNRD and the unit has agreed to participate in the study, and
- 3. Diagnosed with ROP in any stage in at least one eye.
Exclusion Criteria:
- Infants with missing data for gestational age at birth will be excluded.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Premature infants diagnosed with ROP
Premature infants diagnosed with retinopathy of prematurity (ROP) and treated with aflibercept 0.4 mg using the Eylea 40 mg/mL prefilled syringe (PFS) in combination with the PICLEO paediatric dosing device (PDD) after marketing authorisation in UK and included in the National Neonatal Research Database (NNRD).
|
Eylea 40 mg/mL solution for injection in pre-filled syringe.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants treated with Eylea PFS+PDD upon completion of 1- or 3-years following market introduction
Time Frame: From market introduction of Eylea PFS+PDD in UK up to 3 years
|
|
From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summary of patient characteristics reported as number of participants with different categories
Time Frame: From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Birth weight (in categories), sex, gestational age in weeks (in categories), ethnicity, etc.
|
From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Summary of maternal factors reported as number of participants with different categories
Time Frame: From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Problems during pregnancy with mother, problems during pregnancy, mode of delivery, meconium stained liquor at delivery, etc.
|
From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Summary of comorbidities reported as number of participants with different categories
Time Frame: From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Brain injury, necrotising enterocholitis, pulmonary hemorrhage, chronic lung disease, etc.
|
From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Summary of clinical condition and resource utilization reported as number of participants with different categories
Time Frame: From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Respiratory support (mode of ventilation), cardiovascular (inotropic support), feeding (parenteral and enteral nutrition)
|
From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Summary of clinical condition and resource utilization reported as days
Time Frame: From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Intensive care days, invasive ventilation days, parenteral nutrition days
|
From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Summary of outcomes of the premature infants reported as number of participants with different categories
Time Frame: From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Survival to discharge from neonatal care (Y/N); Discharge, death, transferred to another hospital (in categories)
|
From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Summary of ocular disease and treatment reported as number of participants with different categories
Time Frame: From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Number of Eylea injections in the neonatal unity, ROP surgery, ROP stage, ROP clock hours, ROP Max zone, etc.
|
From market introduction of Eylea PFS+PDD in UK up to 3 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Infant, Newborn, Diseases
- Pregnancy Complications
- Obstetric Labor Complications
- Obstetric Labor, Premature
- Infant, Premature, Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Retinal Diseases
- Premature Birth
- Retinopathy of Prematurity
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Aflibercept
Other Study ID Numbers
- 22539
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preterm Infants
-
Hadassah Medical OrganizationWithdrawnPreterm Infants With White Matter Damage | Preterm Infants Developing Normally
-
Children's Hospital of Fudan UniversityCompleted
-
Walid El-NaggarUnknown
-
Abbott NutritionCompleted
-
Mansoura UniversityCompletedPreterm Infants
-
Seoul National University HospitalRecruitingPreterm InfantsKorea, Republic of
-
Baskent UniversityUnknownPreterm InfantsTurkey
-
Nantes University HospitalTerminated
Clinical Trials on Aflibercept (Eylea)
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Hadassah Medical OrganizationBayerUnknownNeovascular Age-related Macular DegenerationIsrael
-
McMaster UniversityActive, not recruiting
-
Seoul National University HospitalCompletedAge-Related Macular DegenerationKorea, Republic of
-
St. Erik Eye HospitalUnknownBranch Retinal Vein Occlusion With Macular EdemaSweden
-
Samsung Bioepis Co., Ltd.CompletedNeovascular Age-related Macular DegenerationCzechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
-
BayerCompleted
-
Alvotech Swiss AGActive, not recruitingNeovascular (Wet) AMDSlovakia, Czechia, Georgia, Japan, Latvia
-
Bioeq GmbHCompletedNeovascular Age-related Macular DegenerationBulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia